Clinical trialEPhase 1Unknown
Immunotherapy of CD8+NKG2D+ AKT Cell With Chemotherapy to Pancreatic Cancer
A Randomized, Double Blinding, Placebo-Controlled Clinical Trials of CD8+NKG2D+ AKT Cell Immunotherapy to the Pancreatic Cancer Patients Treated With Adjuvant Chemotherapy
- Outcome
- Outcome unknown
- Phase
- EPhase 1
- Status
- Unknown
- Study type
- Interventional
- Start
- August 2016
- Expected end
- August 2019
- Enrollment
- 72 participants
- Sites
- 2
- Primary outcomes
- Disease-free survival
- Sponsor
- Other
- Results posted
- No
- Last update
- 11 October 2016
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
A Prospective Study on the Efficacy and Safety of CD8+NKG2D+ AKT cell immunotherapy to the pancreatic cancer patients treated with adjuvant chemotherapy.